Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas.
Haonan Yu, Xiangyuan Bao, Yian Gu...
https://pubmed.ncbi.nlm.nih.gov/40259061Actively Recruiting
Age: 18Years - 80Years
All Genders
Healthy Volunteers
ID06725693
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
Led by Tianjin Medical University · Updated on 2025-02-11
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
T
Tianjin Medical University
Lead Sponsor
T
Tianjin Medical University General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the use of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) to diagnose primary and metastatic lesions in patients with various GLP-1 receptor-related diseases, including tumors such as insulinoma. This observational study aims to measure how well this imaging method can detect disease by analyzing uptake values and diagnostic accuracy. Participants receive a single intravenous injection of 68Ga/18F-Exendin 4 followed by PET/CT imaging within a specified timeframe. This imaging procedure is used either for initial assessment or to detect recurrence of the disease. The study measures standardized uptake values and evaluates diagnostic performance including sensitivity and specificity. During the study, participants undergo PET/CT scans and their lesions are quantified by maximum standardized uptake value (SUVmax). Researchers analyze diagnostic effectiveness within 30 days after the scan. Participation involves providing informed consent and completing the imaging procedure. Safety and diagnostic outcomes are monitored throughout the study period, which lasts until November 2027.
CONDITIONS
Brief Title
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
Who Can Participate
Age: 18Years - 80Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Patients with suspected, newly diagnosed, or previously treated malignant tumors supported by MRI, CT, tumor markers, or pathology reports
- Patients scheduled to undergo Exendin 4 PET/CT scan
- Patients able to provide informed consent and assent according to ethics guidelines
You will not qualify if you...
- Patients with non-malignant lesions
- Pregnant patients
- Patients unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Within 30 days after screening
Participants receive a single intravenous injection of 68Ga/18F-Exendin 4 and undergo PET/CT imaging to assess GLP-1R-related disease.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China, 300052
Actively Recruiting
Loading map...
Research Team
Q
Qiusong Chen, MD
H
Haonan Yu, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here